Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

131 trials with published results (15%)

Research Maturity

603 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.7%

33 terminated out of 896 trials

Success Rate

94.8%

+8.2% vs benchmark

Late-Stage Pipeline

14%

122 trials in Phase 3/4

Results Transparency

22%

131 of 603 completed with results

Key Signals

131 with results95% success33 terminated

Data Visualizations

Phase Distribution

637Total
Not Applicable (235)
Early P 1 (4)
P 1 (151)
P 2 (125)
P 3 (70)
P 4 (52)

Trial Status

Completed603
Unknown117
Recruiting67
Terminated33
Not Yet Recruiting28
Active Not Recruiting24

Trial Success Rate

94.8%

Benchmark: 86.6%

Based on 603 completed trials

Clinical Trials (896)

Showing 20 of 20 trials
NCT05007821Phase 2Completed

Linezolid Dosing Strategies in Drug-Resistant TB

NCT07784894Phase 1RecruitingPrimary

A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential

NCT06314386Not ApplicableEnrolling By InvitationPrimary

Systems Analysis and Improvement Approach to Prevent TB

NCT07656012Phase 2Not Yet RecruitingPrimary

Re-evaluating the Duration in Children of TB Treatment

NCT05586230Phase 1CompletedPrimary

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

NCT07293455Not ApplicableRecruitingPrimary

Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia

NCT04121026Not ApplicableCompletedPrimary

Validation of a Tuberculosis Treatment Decision Algorithm in HIV-infected Children (TB-Speed HIV)

NCT04052022RecruitingPrimary

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

NCT03042754Not ApplicableActive Not RecruitingPrimary

Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

NCT07818824Phase 1Not Yet RecruitingPrimary

A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults

NCT06497465Phase 3RecruitingPrimary

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

NCT05842161Not ApplicableRecruiting

South Africa Smoking Cessation and Engagement in HIV/TB Care Care

NCT04618198Phase 3CompletedPrimary

Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa

NCT07118059Phase 2RecruitingPrimary

Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial

NCT05941052Not ApplicableRecruitingPrimary

Assessing Diagnostics At Point-of-care for Tuberculosis

NCT05989802Not ApplicableRecruitingPrimary

Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)

NCT01212003Recruiting

Training Protocol on the Natural History of Tuberculosis

NCT04926922CompletedPrimary

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

NCT06062238Phase 3Active Not RecruitingPrimary

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

NCT02563327Phase 3CompletedPrimary

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Scroll to load more

Research Network

Activity Timeline